Non-Steroidal Anti-Inflammatory Drug Use and Colorectal Polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Non-Steroidal Anti-Inflammatory Drug Use and Colorectal Polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
复制标题
DOI:
10.1038/ajg.2010.349
复制
发表时间:
2010-12-01
影响因子:
9.8
通讯作者:
Huang, Wen-Yi
中科院分区:
文献类型:
--
作者:
Johnson, Christine Cole;Hayes, Richard B.;Huang, Wen-Yi
OBJECTIVES: Non-steroidal anti-inflammatory drugs (NSAIDs) have been documented in animal and human studies to reduce risk for colorectal cancer and adenomatous polyps, but risk modification for subgroups of the population and effects on hyperplastic polyps have been less studied.METHODS: Data on recent use of two frequently ingested NSAIDs, aspirin and ibuprofen, were collected at baseline from participants aged 55-74 years in the 10 centers of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Participants randomized to the intervention arm of the trial received a flexible sigmoidoscopy during a baseline examination. Follow-up of detected polyps was accomplished outside the Trial setting and relevant records were sought and abstracted. Cases (n = 4,017) included subjects with a biopsy-proven polyp in the left side of the colon (descending colon, sigmoid, and rectum) detected as a consequence of PLCO screening; controls (n = 38,396) were subjects with no left-sided colon polyp.RESULTS: Regular use of aspirin (>= 4 times/month) in the past year was inversely associated with hyperplastic polyps (odds ratios (OR) = 0.8, 95% confidence interval (CI) = 0.7-0.9), adenomatous polyps (OR = 0.8, 95% CI = 0.8-0.9), and advanced adenomas (OR = 0.8, 95% CI = 0.7-0.9). As frequency of aspirin use increased, the prevalence of polyps decreased significantly for each histological classification (P for trend = 2 times/day) was 0.6 (95% CI = 0.5-0.8), as opposed to 0.9 (95% CI = 0.8-1.1) in females. The protective effects of NSAIDs for females were apparent only among those with body mass index (BMI)